RxDoctor Payments Data

Stephanie Dove

Family · Fayetteville, NCNPI 1134626096

Payments from drug & device makers

$939in general payments, 2019–2025

Across 35 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$333
  • Scpharmaceuticals Inc.$125
  • Avion Pharmaceuticals$63
  • Pfizer$57
  • AbbVie$54
  • Mylan Specialty L.p.$39
  • plus $268 from 10 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$82,173
Medicare patients
426
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$124,015
JardianceEmpagliflozin55$43,938
XareltoRivaroxaban40$38,625
EntrestoSacubitril/Valsartan26$24,269
FarxigaDapagliflozin Propanediol11$15,154
Repatha SureclickEvolocumab15$12,839
Pentoxifylline127$5,468
Metoprolol Succinate138$2,014
Rosuvastatin Calcium133$1,869
Atorvastatin Calcium211$1,792
Ranolazine ErRanolazine15$1,789
ClopidogrelClopidogrel Bisulfate169$1,779
Cilostazol98$1,702
Nifedipine ErNifedipine53$1,027
Diltiazem 24hr ErDiltiazem Hcl30$1,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$124,015120 claims
Boehringer IngelheimJardiance$333$43,93855 claims
Johnson & JohnsonXarelto$12$38,62540 claims
AstraZenecaFarxiga$24$15,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →